Context Therapeutics Inc. (CNTX) Research

Context Therapeutics Inc. (CNTX) is a biopharmaceutical firm in the clinical development stage, dedicated to advancing cancer treatments specifically for women in the United States. Its leading investigational therapy is onapristone extended release (ONA-XR). This compound functions as a potent and selective antagonist of the progesterone receptor, aiming to counteract the resistance often encountered with various cancer therapeutics, particularly anti-estrogen therapies, in hormone-dependent female cancers. The company is also progressing with CLDN6xCD3 bsAb, a bispecific monoclonal antibody designed to target both CD3 and Claudin 6 antigens. Its mechanism involves redirecting T-cell-mediated destruction towards malignant cells that express CLDN6. Furthermore, Context Therapeutics Inc. holds a collaboration and licensing agreement with Integral Molecular, Inc. This partnership focuses on the development of an anti-claudin 6 bispecific monoclonal antibody for the treatment of gynecologic cancers. Established in 2015, Context Therapeutics Inc. operates out of its headquarters in Philadelphia, Pennsylvania.

Market snapshot

Symbol
CNTX
Price
$0.63
Day change
+5.32%
Market cap
$58.1M
P/E ratio
-1.50x
52-week range
0.56-3.62
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$5.25

Recent news

  • Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study

    Context Therapeutics Inc. (NASDAQ:CNTX) on Monday released interim Phase 1 data for CTIM-76, its CLDN6 x CD3 T-cell engaging bispecific antibody, showing early signs of efficacy and a favorable safety profile in patients with advanced, late-line platinum-resistant ovarian cancer.

Peer companies

  • Clene Inc. (CLNN)
  • Connect Biopharma Holdings Limited (CNTB)
  • InflaRx N.V. (IFRX)
  • ImageneBio Inc (IMA)
  • Kalaris Therapeutics Inc (KLRS)
  • MacroGenics, Inc. (MGNX)
  • Oramed Pharmaceuticals Inc. (ORMP)
  • Ovid Therapeutics Inc. (OVID)

Recent insider activity

  • Levit Alex C. — A-Award (270000 shares) on 2026-02-19
  • Minai-Azary Jennifer Lynn — A-Award (275000 shares) on 2026-02-19
  • Chagin Karen Deborah — A-Award (290000 shares) on 2026-02-19
  • Lehr Martin A. — A-Award (815000 shares) on 2026-02-19
  • Pasternak Andy — A-Award (138900 shares) on 2025-06-12

Open Context Therapeutics Inc. (CNTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.